Youtor
Ibrutinib Venetoclax amp Obinutuzumab to Treat Chronic Lymphocytic Leukemia CLL Dr Woyach
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=nmyvruCdBqQ
In the setting of the COVID-19 pandemic, progression-free survival for older chronic lymphocytic leukemia (CLL) patients treated for the first time with ibrutinib + venetoclax + obinutuzumab, was not superior to the treatment option of ibrutinib + obinutuzumab. However, many patients in the ibrutinib + venetoclax + obinutuzumab arm did achieve undetectable measurable (minimal) residual disease (MRD). • Dr. Jennifer Woyach from the Ohio State University and colleagues presented the results at the American Society for Clinical Oncology (ASCO) Annual Meeting 2023. • Read the full article on CLL Society's website at: https://cllsociety.org/2023/09/combin... • __________________________________________________________________________________________ • CLL Society Website: https://cllsociety.org/ • Facebook: / cllsociety • Twitter: / cllsociety • LinkedIn: / cll-society
#############################
